Written Question · S2W-07038 · Session 2
What measures it is taking to encourage NHS boards not to use vaccines containing mercury.
The question
To ask the Scottish Executive what measures it is taking to encourage NHS boards not to use vaccines containing mercury.
The answer
The Joint Committee onVaccination and Immunisation (JCVI), a statutory independent expert advisorycommittee, advises UK health departments on matters relating tovaccination and immunisation.
The UK Medicines andHealthcare products Regulatory Agency (MHRA), with advice from the independentexpert advisory committee, the Committee on Safety of Medicines (CSM), isresponsible for ensuring that vaccines are safe and effective for those who usethem.
The CSM has reviewed thesafety of vaccines which contain thiomersal (a preservative compound thatincludes ethylmercury) on a number of occasions, most recently in February 2003.It advised that, with the exception of hypersensitivity reactions, thattypically include skin rashes or local swelling at the site of the injection,there is no evidence of harm from the levels of thiomersal contained in somevaccines. It concluded that the balance of benefits and risks ofthiomersal-containing vaccines therefore remains overwhelmingly positive.
As such, some thiomersal-containingvaccines are currently recommended for use in the UK because,on the basis of the best scientific evidence and advice, they provide the mosteffective clinical protection against a range of serious diseases.
As a precautionary measure,however, to reduce avoidable exposure to mercury in general, it has been agreedon a European-wide basis that, even though there is no evidence of toxicity, asa precautionary measure, thiomersal should be substituted or reduced as soon assafe and effective thiomersal-free alternatives become available and licensedfor use in the UK. Work is proceeding to this end.
This approach has beenendorsed by the JCVI, the CSM, the MHRA and the Executive.
The UK Medicines andHealthcare products Regulatory Agency (MHRA), with advice from the independentexpert advisory committee, the Committee on Safety of Medicines (CSM), isresponsible for ensuring that vaccines are safe and effective for those who usethem.
The CSM has reviewed thesafety of vaccines which contain thiomersal (a preservative compound thatincludes ethylmercury) on a number of occasions, most recently in February 2003.It advised that, with the exception of hypersensitivity reactions, thattypically include skin rashes or local swelling at the site of the injection,there is no evidence of harm from the levels of thiomersal contained in somevaccines. It concluded that the balance of benefits and risks ofthiomersal-containing vaccines therefore remains overwhelmingly positive.
As such, some thiomersal-containingvaccines are currently recommended for use in the UK because,on the basis of the best scientific evidence and advice, they provide the mosteffective clinical protection against a range of serious diseases.
As a precautionary measure,however, to reduce avoidable exposure to mercury in general, it has been agreedon a European-wide basis that, even though there is no evidence of toxicity, asa precautionary measure, thiomersal should be substituted or reduced as soon assafe and effective thiomersal-free alternatives become available and licensedfor use in the UK. Work is proceeding to this end.
This approach has beenendorsed by the JCVI, the CSM, the MHRA and the Executive.
In the Official Report
No contribution in the Official Report cites S2W-07038 by reference.